Business
Shareholder Circular and Notice of General Meeting
Shareholder Circular and Notice of General Meeting.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 4819Y ValiRx PLC 06 December 2017 \n\n \n \nVALIRX PLC\n(\"ValiRx\" or \"the Company\")\n \nSHAREHOLDER CIRCULAR AND NOTICE OF GENERAL MEETING\n \nLondon, UK, 6 December 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology announces that it has recently published and posted to shareholders a circular and notice convening a General Meeting of ValiRx Plc to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 9:00 a.m. on 21 December 2017.\n \nThe directors will propose at the General Meeting shareholder resolutions seeking shareholder authority to allot shares and the dis-application of pre-emptive rights.\n \nA copy of the Circular will be available on the Company's website shortly: www.valirx.com\n \n- ENDS -\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nDr Satu Vainikka, Chief Executive\nTarquin Edwards, Investor Relations\n \n\n\nwww.valirx.com\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nLiam Murray / Jo Turner\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBeaufort Securities Limited (Broker)\n\n\nTel: +44 (0) 20 7382 8300\n\n\n\n\nJon Belliss\n\n\n\n\n\n\n\n \nNotes for Editors\nAbout ValiRx Plc \n \nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention. \n \nThe Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. \n \nValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent ...